

1 *Article*

2 **Assessment of Attitude and Hesitancy Towards Covid-19 Vaccine among**
3 **Hepatitis B and C Patients in Pakistan**

4

5 **Short Title:** Refusal to covid-19 vaccine among viral Hepatitis patients in Pakistan

6

7 Farheen Shafiq¹,

8 <https://orcid.org/0000-0003-3658-9729>

9 Mahreen ul Hassan^{2*}

10 <https://orcid.org/0000-0002-5524-9765>

11 Sadia Butt³

12 <https://orcid.org/0000-0002-3631-3354>

13 Sadia sidique⁴

14 <https://orcid.org/0000-0001-6483-3579>

15 Nazia Akbar⁵

16 <https://orcid.org/0000-0003-2203-4933>

17 Azra⁶

18 <https://orcid.org/0000-0002-3088-2345>

19 Irshad Rehman⁷

20 <https://orcid.org/0000-0002-2724-6946>

21

22 ***Correspondence:**

23 **Dr. Mahreen ul Hassan**

24 <https://orcid.org/0000-0002-5524-9765>

25 Email: microkust@sbbwu.edu.pk

26 Contact no. 03348483041

27 78 Western Bank

28 Firth Court

29 Department of Bioscience

30 University of Sheffield, UK

31 S10 2TN

32 Sheffield, South Yorkshire

33 United Kingdom

34 **ABSTRACT**

35 **OBJECTIVE:** The research aimed to evaluate the attitude and perceptions towards the covid-19
36 vaccine among Hepatitis B and C patients in Peshawar, Khyber Pakhtunkhwa, Muzaffarabad,
37 Azad Kashmir, Pakistan.

38 **METHODS:** A survey-based study was adopted to evaluate the attitude of Hepatitis B and C
39 patients towards immunization against covid-19 in Peshawar (KPK) and Muzaffarabad (AJK)
40 cities of Pakistan. The study continued from January 2020 to February 2021. Participants were
41 also assessed for their perception towards covid-19 vaccination.

42 **RESULTS:** A total of 839 (33.6%) individuals participated in the study. About 52 % of
43 Hepatitis B patients were immunized against Covid-19, whereas the number of Hepatitis C
44 patients was recorded at around 48%. About 53.7 % of participants refused to get the vaccine
45 without any reason. About 63.2% of patients showed concern about the insufficient data
46 available on the vaccine safety and efficacy published by the Public Health Department.
47 Individuals with higher education were observed to be more open towards vaccination than those
48 without a formal education. More than half of the participants (61.5 %) were concerned about the
49 interference of the vaccine with their hepatitis treatment whereas 54.7 % patients refused vaccine
50 because of a poor liver condition.

51 **CONCLUSIONS:** The data indicated that limited data availability regarding the vaccine
52 efficacy in viral hepatitis patients and negative attitudes of people toward covid-19 vaccination is
53 the main cause of Covid-19 vaccination refusal among hepatitis B and C patients.

54 **DESCRIPTORS:** Hepatitis B, Hepatitis C, covid-19, immunization, vaccine refusal, Pakistan.

55 **INTRODUCTION**

56 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the 7th human coronavirus,
57 was reported in Wuhan, Hubei province, China, in January 2020¹⁻². In early 2020, the World
58 Health Organization (WHO) declared it a pandemic and requested the world to take strict
59 measures to control the disease as there was no effective treatment available, and the death toll
60 was rising every hour across the world³.

61 The SARS-CoV-2 is an airborne virus which can be transmitted through air therefore effective
62 preventive measures like social distancing, frequent handwash and wearing a mask in the
63 absence of a valid treatment or vaccine to control the disease was imperative⁴.

64 Patients with covid-19 may have abnormal liver function or hepatic dysregulation, which may
65 identify as cholestasis, hepatitis, or both. In an early study from China, increased total bilirubin
66 was observed in 18 (18%) patients and higher serum alanine aminotransferase (ALT) was
67 recorded in 28 (28%) of 99 individuals with covid-19⁵.

68 It is suggested that SARS-CoV-2 may exacerbate liver damage in individuals with chronic viral
69 hepatitis⁶. According to Xu et al.⁷ (2020), liver dysfunction occurs more often and more severely
70 as covid-19 progresses. Liver function tests are typically normal or somewhat raised in the early
71 stages of SARS-CoV-2 infection. Histological examination of the liver reveals syncytial
72 multinuclear hepatocytes, microvascular steatosis, and little lobular and portal activity.

73 The cytokine storm caused by the progression of severe covid-19 cases requiring strong
74 immunosuppressive therapy has raised the problem of recurrence of HBV infections in the
75 patients with a history of HBV⁸.

76 In a study conducted by Ronderos et al.⁹ (2021), patients with covid-19 having history of
77 hepatitis C virus (HCV) or seropositivity for HCV infection have an increased susceptibility to
78 SARS-CoV-2 infection, which is a strong predictor of in-hospital mortality regardless of
79 preexisting conditions, laboratory results upon admission, or the severity of covid-19-induced
80 liver injury.

81 With an estimated 9.8 million chronic HCV patients, Pakistan has the second-highest burden of
82 HCV infection in the world¹⁰. Unscreened blood transfusions, a history of hospitalization, dental
83 work, tattooing, body piercing, the use of injections, and a history of surgery are the main risk
84 factors for the transmission of HCV¹¹. According to government statistics, around 2.5% of
85 Pakistan's population was infected with HBV in 2008. There was a 5% rise in HCV-related
86 mortality and an 8% increase in HBV-related deaths between 2015 and 2019¹⁰.

87 According to World Health Organization vaccination is an easy, safe, and efficient way to avoid
88 infection especially in the absence of an effective therapy as in the case of covid-19¹².

89 Vaccination is the most significant medical intervention in the human history which has largely
90 eradicated the infectious diseases that formerly claimed the lives of millions of people¹³.
91 Currently, more than 30 infectious diseases could be avoided with the use of vaccinations¹⁴.
92 According to an estimation, the immunization against covid-19 have prevented thousands of
93 deaths and saved millions of people from getting infection in England and United States till June
94 2021¹⁵⁻¹⁶.

95 Pakistan is also badly affected by covid-19 pandemic. Currently there are 1,573,922 confirmed
96 covid-19 cases from which 2,928 are marked as active in different areas of Pakistan and about
97 30,625 causalities have been observed from 2020 to date¹⁷.

98 The Chinese government sent more than 500,000 doses of the Chinese Sinopharm vaccine to
99 Pakistan in February 2021, and the Pakistani government opted to prioritize immunizing
100 frontline healthcare workers¹⁸. Pakistan initially restricted immunization to those aged 18 and
101 older before expanding the program. The government was placing a higher priority on heavily
102 populated metropolitan centers and "hotspot" locations, where the coronavirus transmits more
103 rapidly than in more distant rural communities¹⁹. It is estimated that about 69.9 % population in
104 Pakistan has taken at least on dose of covid-19 vaccine. The number is not very discouraging but
105 nature of disease and its transmission along with the emergence of new Corona virus variants
106 every 6 month makes it crucial to get the entire population immunized in limited time to control
107 the disease¹⁷.

108 Vaccine hesitancy is one of the top 10 global health problems, according to the World Health
109 Organization²⁰. Fear of the covid-19 vaccination is a growing problem that Pakistan is also
110 dealing with. It is one of the nations with lowest vaccination rates²¹. Myths such as the vaccine
111 causes sterility, the pandemic is a foreign conspiracy, or the virus is harmless are common
112 contributors to the hesitation towards covid-19 vaccination²².

113 In current study have sought to understand the current level of awareness of covid-19
114 transmission, symptoms, and preventive measures specifically among Hepatitis B and C patients.
115 The study also aimed to identify the risk variables that contribute to ambivalence towards covid-
116 19 vaccination among hepatitis patients residing in KPK and AJK, Pakistan.

117 **METHODOLOGY**

118 **Study Location and Settings**

119 Survey-based research was conducted in Peshawar and Muzaffarabad from January 2020 to
120 February 2021. A questionnaire was prepared for the study. An epidemiologist, field surveyor,
121 and health care practitioner assisted in the development of a questionnaire. To calculate the
122 reliability score and Cronbach alpha, the questionnaire was pretested in a pilot study.

123 **Sample Size and Exclusion Criteria**

124 For the evaluation of the knowledge and perception of the hepatitis B and C patients toward
125 covid-19 and the vaccination program the questionnaire was distributed throughout the
126 community where these patients were easily accessible. Hepatitis B and C patients age 18 years
127 and above were deemed eligible. Participants who refused to provide any information or who
128 were temporary residents were barred from participating. The questionnaire was created to
129 identify potential challenges to covid-19 immunization.

130 **Designing and Validating the Questionnaire**

131 Following a thorough review of the relevant literature, a questionnaire was designed. It was
132 composed in English, then translated into Urdu and Pushto for participants before translated back
133 to English for analysis. The questionnaire was divided into two sections, each with 16 questions.
134 Section one had ten questions that assessed demographic data such as age, gender, race, income,
135 marital status, and so on. The next section included 16 questions designed to test participants'
136 knowledge and perceptions about covid-19 and its vaccination.

137 **Statistical Analysis**

138 Data evaluation was performed through SPSSv21 statistical package.

139 **Ethical Approval and Consent of Participants**

140 This study was approved by the Research and Ethics Committee of Shaheed Benazir Bhutto
141 Women University Peshawar, Pakistan. A filled and signed informed consent form was collected
142 from each participant before the participation. All the information of the participants is kept
143 confidential.

144 **RESULTS**

145 **Demographic Details of the Respondents**

146 A total of 839 responses were collected, of which 36.1% (303) were female and 63.9% (536)
147 were from male respondents. Table 1 displays the demographic data (age, gender, place of
148 residence, educational background, occupation, and monthly income) of the survey respondents.
149 About 48% responses were collected from Hepatitis B patients whereas the response rate of
150 Hepatitis C patients was 52 %. Age-wise most of the patients were young (57.1%) while it was
151 observed that the number of respondents were mostly male (63.9 %) that could be due to the
152 cultural barriers in the area. The data generated through this study revealed the about 35.5%
153 hepatitis patients were still unvaccinated due to various reasons.

154 **Table 1. shows demographic data frequencies of the participants. (n = 839).**

155 **Approved Vaccines in Pakistan**

156 In Pakistan, every person above age 18 was bound to get one of the approved Covid-19 vaccines
157 to minimize the devastating effects of pandemic according to National Action Plan for Corona
158 virus disease (covid-19) Pakistan^a (Table S1). For the purpose, Government of Pakistan worked
159 tirelessly making the best vaccines widely available to the public. As a result, about 10% of the
160 population received the first by the mid of year 2021. The information presented in Table 6 was
161 generated as a secondary data by utilizing all the reliable resources available e.g., National
162 Institute of Health Pakistan^b, WHO^c and dedicated website for covid-19 related information by
163 the Ministry of National Health Services Pakistan^d. Likewise, it was advised that everyone with a
164 known underlying disease, including those with hepatitis, immunize themselves against covid-
165 19.

166 **Table 2- Commercially available Vaccines approved by the Government of Pakistan.**

167 It was observed during the study that around 65 % participants were fully immunized (Figure
168 1a), and rest of the participants refused after taking first dose to immunize due to some reasons
169 (Figure 1b).

^a <https://www.nih.org.pk/wp-content/uploads/2020/04/COVID-19-NAP-V2-13-March-2020-1.pdf>

^b <https://www.nih.org.pk/public/novel-coronavirus-2019-ncov>

^c <https://covid19.who.int/region/emro/country/pk>

^d <https://covid.gov.pk/>

170 **Figure 1a. No. of patients receiving covid-19 vaccines from approved pharmaceuticals. b. No. of**
171 **Patients refused to get immunized.**

172 The main objective of this study was to evaluate the hepatitis patients' awareness of the covid-19
173 vaccination and the fears that were keeping them from receiving the vaccine. For the purpose a
174 derailed interview was arranged with each participant and their answer were recorded for further
175 analysis.

176 **Attitude and Perceptions towards covid-19 vaccination**

177 The questionnaire was split in two parts i.e., part A (Table 3a) where patients were assessed why
178 they chose to get immunized against covid-19. Part B (Table 3b) was specifically designed for
179 the patients who refused to take covid vaccine.

180 The questionnaire A analysis revealed that most participants (79.5%) were happy to get
181 vaccinated because there were no charges of that vaccine as compared to the Hepatitis C vaccine
182 available in the markets (Table 3a). Many participants (76.9%) believed that the vaccine would
183 protect them from covid-19. About 76.5% people claimed that they were encouraged when they
184 realized that other hepatitis patients were also getting vaccine. As a reflection of their confidence
185 in their doctors, 469 out of 710 people (71.2% of the total) vaccinated themselves after medical
186 professionals encouraged them to do so. Yet 374 (56.8%) patients showed concern about the
187 insufficient data available on the vaccine safety and efficacy published by the Public Health
188 Department.

189 **Table 3a. Assessment of patients choosing covid-19 vaccine for protection. b. Question statements to**
190 **assess Hepatitis patient for refusing covid-19 vaccine.**

191 There were many explanations given by individuals when asked why they didn't want to be
192 vaccinated (Table 3b). About 74.1 % of participants had a view that precautionary measures like
193 social distancing and wearing a mask or visor could protect them from getting covid-19
194 infection. Some people refused (63.2 %) to get vaccination simply because they did not have
195 enough information about the vaccine due to unavailability of literature regarding outcomes of
196 covid vaccination. Interestingly, half of the patients (53.7 %) were simply against any type of
197 immunization whatever vaccine it was and perceived the immunization as a part of foreign
198 agenda. However, 181 (61.5 %) patients were worried that the vaccine might interact with their
199 hepatitis therapy as there is no published data available which can prove it wrong; people don't

200 believe in assumptions especially in case of a health-related issue. The study also revealed that
201 about 54.7 % of total participants were concerned about their liver condition as they were already
202 dealing with a liver infection. The fear of an over-burdened liver cannot be overlooked. More
203 than half (57.5 %|) of the patients who were against the vaccination were of view that there is no
204 point to get vaccination if it is not protecting you against the infection. Around 58.5 %
205 participants were of view that they have immunity against the disease due to the previous covid
206 infection. Unfortunately, some patients (12.2 %) got allergic reactions after getting first dose due
207 to which they feared to try another type of covid vaccine.

208 **Correlation between various parameters**

209 Table 4a showed positive and negative correlation between various parameters of hepatitis
210 patients with respect to the trend towards covid-19 vaccine. A very strong relationship (.104**)
211 was found among the self-employed people toward the covid vaccine as compared to the people
212 related to other sources of income. The trend showed that there was a significant difference
213 among the people of various education levels. The participants having higher levels of education
214 were more agreed to get vaccinated against covid-19 as compared to others. Surprisingly,
215 participants having high incomes were showed a highly significant difference and were less
216 likely to get vaccinated (-.119**) and same was the trend seen in case of females (-0.018). All
217 age groups showed a weak relationship between patients and their attitude towards the covid
218 vaccine. A negative correlation was seen in case of ethnicity and location. It was revealed that
219 participants from Punjabi origin were reluctant (-0.064) to get vaccinated as compared to
220 Kashmiri and Pathans. The study also revealed that less people from Muzaffarabad AJK were get
221 vaccinated (-0.022) than those from Peshawar, KPK.

222 **Table 4a. Correlation between different variables of Hepatitis B and C patients with the**
223 **covid-19 vaccine approval or rejection. b. Spearman correlation between different variables**
224 **and covid-19 vaccine.**

225 **Relationship between Demographic Characteristics and Responses of Participants**

226 Associations of different characteristics were made against the participants' knowledge of covid-
227 19 (Table 4b). First, education levels of the participants were evaluated against the use of mask
228 by the participants. It was observed that the use of mask was significantly less among individuals
229 with lower education levels as compared to individuals with higher education (P 0.064).

230 However, non-significant relationships were present between education level and other aspects
231 of our study such as attending social gatherings, frequent hand washing, and covid-19 as a
232 bioweapon. Second, income levels of the participants were analyzed against various factors. A
233 significant relationship was found among the income level of the participant and their affinity to
234 join social gatherings during the covid-19 pandemic. It was observed that respondents with lower
235 income levels were more likely to attend gatherings as compared to higher income respondents.
236 Similarly, income level was also found to be associated with the subjects' use of mask.
237 Participants with higher income levels were wearing N95 and surgical masks, whereas cloth
238 masks were usually used by lower-income respondents. Terminally higher- and lower- income
239 category subjects wore fewer masks as compared to middle-income-range groups. More
240 participants in the lower-income category had to leave their jobs or had their business shut down
241 during the covid-19 pandemic as compared to higher-income respondents. Likewise, more
242 women have left their jobs as compared to their male counterparts. However, business shutdown
243 trend mainly affected the male gender. Moreover, the males were found to wear mask more often
244 than the females. Females usually wore N95 masks, whereas male respondents relied more on
245 surgical masks or cloth masks. On the contrary, no significant associations were present among
246 all the characteristics with hand-washing practices and the use of covid-19 as bioweapons.

247 **DISCUSSION**

248 In Pakistan, the combined number of persons infected with hepatitis B virus (HBV) and hepatitis
249 C virus (HCV) is over 15 million¹². Free treatment for viral hepatitis is being offered throughout
250 the nation thanks to the Hepatitis Prevention and Treatment Program and other government-
251 funded initiatives²³. At a time when a worldwide effort to eliminate viral hepatitis was essential,
252 covid-19 placed a significant burden on national healthcare systems. According to Mustafa et
253 al.²⁴ (2021), with the rise of covid-19 cases in early 2020, a sharp decline in visits of viral
254 hepatitis patients was observed to their respective clinics across Pakistan. However, an estimated
255 325 deaths because of viral hepatitis were also reported each day. The data suggested that there
256 was a clear shift of priority towards the Covid patients due to unavailability of a valid treatment
257 and increased number of casualties.

258 Current study is unique as it primarily examined how the Hepatitis B and C patients residing in
259 Peshawar KP and Muzaffarabad AJK have responded to the covid-19 immunization program.

260 Currently no data is available regarding concerns of hepatitis patients in the area, therefore, we
261 have assessed the participants concerns regarding the vaccine and compared it with the other
262 studies conducted in the world.

263 As described in the Health Belief Mode, the preventive actions, like getting a vaccination,
264 depend on how people see the risks of disease and how they perceive the effectiveness, benefits,
265 and costs of these actions²⁵. Pakistan and Afghanistan are two countries where nation-wide
266 immunization has always been challenging as we have seen in the case of polio eradication
267 program according to Shafique et al.²⁶ (2021). In this study it was initially decided to contact
268 maximum number of viral hepatitis patients residing in the study area. However, it was observed
269 that most of the patients avoid such interviews due to some reasons. Therefore, we could succeed
270 to interview around 839 patients. The survey revealed that majority of the participants (79.5%)
271 were open to vaccination which shows apposite attitude towards the covid-vaccination. The
272 reason might be the easy availability of the vaccine and an active covid-19 eradication program
273 in which healthcare workers are going door to door to make sure everyone has got vaccinated.
274 The results were even better than a similar study conducted by Tahir et al.²⁷ in 2021.

275 However, there are still number of individuals which are not immunized due to some reason
276 which is a real concern. It is also notable that majority of the individuals who participated in this
277 study was between the age of 18 and (57.1 %) which indicates that young generation is more
278 open to express their opinion about health issues. There were mixed responses when the
279 participants were asked whether a patient suffering from viral hepatitis should get immunized.

280 Most of the patients (54.7 %) refused to get fully vaccinated despite the government's strict
281 orders because they were worried about their liver condition. Unfortunately, there is not much
282 data about the effect of covid vaccines on the liver of hepatitis B and C patients specifically.
283 Therefore, it is nearly impossible to persuade a person for getting a vaccination with a poor liver
284 condition. Furthermore, there are some studies that have reported the postvaccination
285 Autoimmune Hepatitis (AIH)²⁸⁻³² which makes it essential to study the health of viral hepatitis
286 patients after vaccination to devise a better strategy for hepatitis patients in order to prevent
287 covid-19.

288 More than half of the patients (57.5 %) who refused to take the 2nd dose individuals believed that
289 covid-19 vaccination might not protect them from the covid-19 infection because they got ill or
290 observed that people contracted infection even getting vaccinated. The concern is authentic;
291 there are many cases reported around the world where vaccines have failed to prevent individuals
292 from the disease. For instance, in a recent study Jain et al.³³ (2021) reported that despite its
293 effectiveness in preventing masses from the adverse effects of covid infection the covid vaccine
294 was not proved suitable for certain individuals and postvaccination infection even deaths have
295 been raised many questions on the efficacy of the vaccine especially in patients with
296 vulnerability.

297 There were a few participants (12.2 %) who were covid against the vaccination because they
298 developed adverse reactions after getting the 1st dose of covid vaccine. This concern was not
299 baseless as many though rare but incidents regarding hypersensitivity reaction to covid vaccine
300 have been reported since 2020 vaccine roll out³⁴.

301 About 218 (74.1 %) out of total participants believed that strict Standard Operating Procedures
302 (SOPs) could prevent them from infection. Their belief was not wrong as we have seen that strict
303 precautionary measures have saved masses when there was no vaccine available during the
304 pandemic back in 2020. In random studies Kissler et al.³⁵ (2020) and Moosa³⁶ (2020) analyzed
305 that social distancing has appeared to be quite effective to contain the covid infection when there
306 was no vaccine available. Similarly, Hsieh et al³⁷. 2020, reported that preventive measures such
307 as social distancing, using Personal Protective Equipment (PPE), and frequent handwashing, etc.
308 at a personal level could be significantly helpful to control the covid infection in the absence of
309 other interventions. However, their approach to avoid covid-19 infection was not realistic. It is
310 impossible to avoid social contact in this fast-paced life and sometimes SOPs are not enough. It
311 is observed in various studies though minimal but there are still chances to get infected by
312 following SOPs only³⁸.

313 **CONCLUSION**

314 It was concluded that despite a successful covid-19 prevention program in Pakistan the concern
315 towards the safety and efficacy of covid vaccine is still there. The study revealed that the reason
316 to refuse vaccination cannot be neglected as they are genuine and need to be addressed carefully.

317 Additionally, addressing the issues regarding vaccine refusal requires genuine data
318 demonstrating the benefits of vaccines in viral hepatitis patients is inevitable in order to resolve
319 the ambiguity related to covid vaccination efficacy.

320 **LIMITATIONS IN STUDY**

321 Despite many efforts for making this study possible, it has a few limitations. First, the study area
322 was confined to only two cities Peshawar and Muzaffarabad which is not enough to portray a
323 clear picture of the current situation in Pakistan. Secondly, the resistance towards covid-19
324 vaccination-related reporting also makes data collection difficult. Natives especially hepatitis
325 patients usually do not want to take part in such studies to avoid stigmatization.

326

327 **REFERENCES**

- 328 1. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL,
329 Chen HD. A pneumonia outbreak associated with a new coronavirus of probable bat
330 origin. *nature*. 2020 Mar;579(7798):270-3.
- 331 2. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, Hu Y, Tao ZW, Tian JH, Pei YY,
332 Yuan ML. A new coronavirus associated with human respiratory disease in China.
333 *Nature*. 2020 Mar;579(7798):265-9.
- 334 3. World Health Organization Coronavirus Disease 2019(COVID-19) Situation Report-97.
335 Available from: [https://www.who.int/docs/default-source/coronaviruse/situation-](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200426-sitrep-97-covid-19.pdf)
336 [reports/20200426-sitrep-97-covid-19.pdf](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200426-sitrep-97-covid-19.pdf).
- 337 4. Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. *Acta Bio Medica: Atenei*
338 *Parmensis*. 2020;91(1):157.
- 339 5. Liao M, Liu H, Wang X, Hu X, Huang Y, Liu X, Brenan K, Mecha J, Nirmalan M, Lu
340 JR. A technical review of face mask wearing in preventing respiratory COVID-19
341 transmission. *Current Opinion in Colloid & Interface Science*. 2021 Apr 1;52:101417.
- 342 6. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Yu T.
343 Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus

- 344 pneumonia in Wuhan, China: a descriptive study. *The lancet*. 2020 Feb
345 15;395(10223):507-13.
- 346 7. Moon AM, Webb GJ, Aloman C, Armstrong MJ, Cargill T, Dhanasekaran R, Genescà J,
347 Gill US, James TW, Jones PD, Marshall A. High mortality rates for SARS-CoV-2
348 infection in patients with pre-existing chronic liver disease and cirrhosis: preliminary
349 results from an international registry. *Journal of hepatology*. 2020 Sep 1;73(3):705-8.
- 350 8. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L, Tai Y.
351 Pathological findings of COVID-19 associated with acute respiratory distress syndrome.
352 *The Lancet respiratory medicine*. 2020 Apr 1;8(4):420-2.
- 353 9. Baroiu L, Anghel L, Tatu AL, Iancu AV, Dumitru C, Le□e AC, Drăgănescu M, Năstase
354 F, Nicule□ E, Fotea S, Nechita A. Risk of hepatitis B reactivation: From biologic
355 therapies for psoriasis to immunosuppressive therapies for COVID-19. *Experimental and
356 Therapeutic Medicine*. 2022 Jun 1;23(6):1-9.
- 357 10. Ronderos D, Omar AM, Abbas H, Makker J, Baiomi A, Sun H, Mantri N, Choi Y,
358 Fortuzi K, Shin D, Patel H. Chronic hepatitis-C infection in COVID-19 patients is
359 associated with in-hospital mortality. *World Journal of Clinical Cases*. 2021 Oct
360 10;9(29):8749.
- 361 11. CGHE (2022). National Hepatitis Elimination Profile for Pakistan: Key Takeaways,
362 National Hepatitis Elimination Profile for Pakistan: Key Takeaways | Coalition for
363 Global Hepatitis Elimination. The Coalition for Global Hepatitis Elimination (CGHE).
364 Available at: [https://www.globalhep.org/news/national-hepatitis-elimination-profile-](https://www.globalhep.org/news/national-hepatitis-elimination-profile-pakistan-key-takeaways)
365 [pakistan-key-takeaways](https://www.globalhep.org/news/national-hepatitis-elimination-profile-pakistan-key-takeaways) (Accessed: October 28, 2022).
- 366 12. Kazmi SA, Rauf A, Shafique F, Asim N, Hassan MU. Kashmiri refugees at the verge of
367 hepatitis B and C epidemic in the State of Azad Jammu and Kashmir, Pakistan. *Revista
368 de Saúde Pública*. 2022 May 6;56.
- 369 13. WHO (2022) Vaccines and immunization, World Health Organization. World Health
370 Organization. Available at: [https://www.who.int/health-topics/vaccines-and-](https://www.who.int/health-topics/vaccines-and-immunization#tab=tab_1)
371 [immunization#tab=tab_1](https://www.who.int/health-topics/vaccines-and-immunization#tab=tab_1) (Accessed: October 29, 2022).
- 372 14. Rappuoli R, Pizza M, Del Giudice G, De Gregorio E. Vaccines, new opportunities for a
373 new society. *Proceedings of the National Academy of Sciences*. 2014 Aug
374 26;111(34):12288-93.

- 375 15. Bärnighausen T, Bloom DE, Cafiero-Fonseca ET, O'Brien JC. Valuing vaccination.
376 Proceedings of the National Academy of Sciences. 2014 Aug 26;111(34):12313-9.
- 377 16. Public Health England, Cambridge University MRC Biostatistics Unit. Direct and
378 indirect impact of the vaccination programme on COVID-19 infections and mortality.
- 379 17. Galvani A, Moghadas SM, Schneider EC. Deaths and hospitalizations averted by rapid
380 US vaccination rollout. The Commonwealth Fund. Issue Briefs. 2021 Jul 7.
- 381 18. Government of Pakistan 2022. Covid-19 health advisory platform by Ministry of
382 National Health Services Regulations and Coordination (2022) COVID. Available at:
383 <https://covid.gov.pk/stats/pakistan> (Accessed: October 28, 2022).
- 384 19. Hashim, A. (2021). Vaccine hesitancy in Pakistan heightens risk of COVID resurgence.
385 Al Jazeera.
- 386 20. Weibel, C. (2021) Pakistan steps up COVID-19 vaccine roll-out, UNICEF Pakistan.
387 Available at: [https://www.unicef.org/pakistan/stories/pakistan-steps-covid-19-vaccine-](https://www.unicef.org/pakistan/stories/pakistan-steps-covid-19-vaccine-roll-out)
388 [roll-out](https://www.unicef.org/pakistan/stories/pakistan-steps-covid-19-vaccine-roll-out) (Accessed: October 27, 2022).
- 389 21. Barello S, Nania T, Dellafiore F, Graffigna G, Caruso R. 'Vaccine hesitancy' among
390 university students in Italy during the COVID-19 pandemic. European journal of
391 epidemiology. 2020 Aug;35(8):781-3.
- 392 22. Abdulsattar, B. (2021) Ipsos survey on vaccine hesitancy in Pakistan - 9th March 2021.
393 Ipsos. Available at: [https://www.ipsos.com/en-pk/ipsos-survey-vaccine-hesitancy-](https://www.ipsos.com/en-pk/ipsos-survey-vaccine-hesitancy-pakistan-9th-march-2021)
394 [pakistan-9th-march-2021](https://www.ipsos.com/en-pk/ipsos-survey-vaccine-hesitancy-pakistan-9th-march-2021) (Accessed: October 27, 2022).
- 395 23. Khan A, Afzal S, Yaqoob A, Fatima R, Haq MU, Junaid K, Nadir A. Epidemiology of
396 viral hepatitis B and C in Punjab, Pakistan: a multicenter cross-sectional study, 2017-18.
397 F1000Research. 2019 Dec 6;8(2065):2065.
- 398 24. Mustafa ZU, Kow CS, Hasan SS. Effect of COVID-19 on viral hepatitis services in
399 Pakistan. The Lancet Gastroenterology & Hepatology. 2021 Mar 1;6(3):163-4.
- 400 25. Janz NK, Becker MH. The health belief model: A decade later. Health education
401 quarterly. 1984 Mar;11(1):1-47.
- 402 26. Shafique F, Nayab H, Asim N, Akbar N, Shafi N, Manzoor S, Eeden FV, Ali S. Attitude
403 and perception towards vaccination against poliomyelitis in Peshawar, Pakistan. Revista
404 de Saúde Pública. 2021 Dec 8;55:104.

- 405 27. Tahir MJ, Saqlain M, Tariq W, Waheed S, Tan SH, Nasir SI, Ullah I, Ahmed A.
406 Population preferences and attitudes towards COVID-19 vaccination: a cross-sectional
407 study from Pakistan. *BMC public health*. 2021 Dec;21(1):1-2.
408 <https://doi.org/10.1186/s12889-021-11814-5>
- 409 28. Palla P, Vergadis C, Sakellariou S, Androutsakos T. Autoimmune hepatitis after
410 COVID-19 vaccination: A rare adverse effect?. *Hepatology (Baltimore, Md.)*. 2022
411 Feb;75(2):489.
- 412 29. Camacho-Domínguez L, Rodríguez Y, Polo F, Gutierrez JC, Zapata E, Rojas M, Anaya
413 JM. COVID-19 vaccine and autoimmunity. A new case of autoimmune hepatitis and
414 review of the literature. *Journal of translational autoimmunity*. 2022 Jan 4:100140.
- 415 30. Bril F, Al Diffalha S, Dean M, Fettig DM. Autoimmune hepatitis developing after
416 coronavirus disease 2019 (COVID-19) vaccine: causality or casualty?. *Journal of*
417 *Hepatology*. 2021 Jul 1;75(1):222-4.
- 418 31. Garrido, I., Lopes, S., Simões, M.S., Liberal, R., Lopes, J., Carneiro, F. and Macedo, G.,
419 2021. Autoimmune hepatitis after COVID-19 vaccine—more than a coincidence. *Journal*
420 *of Autoimmunity*, 125, p.102741.
- 421 32. Efe C, Dhanasekaran R, Lammert C, Ebik B, Higuera de la Tijera F, Aloman C, Rıza
422 Çalışkan A, Peralta M, Gerussi A, Massoumi H, Catana AM. Outcome of COVID-19 in
423 patients with autoimmune hepatitis: an international multicenter study. *Hepatology*. 2021
424 Jun;73(6):2099-109.
- 425 33. Jain VK, Iyengar KP, Ish P. Elucidating causes of COVID-19 infection and related deaths
426 after vaccination. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*. 2021
427 Sep 1;15(5):102212.
- 428 34. Fernandez-Davila N, Taylor MG, Anvari S. Hypersensitivity Reactions to COVID-19
429 Vaccines—Identify High-Risk Children and Vaccinate the Rest. *JAMA pediatrics*. 2022
430 May 1.
- 431 35. Kissler S, Tedijanto C, Lipsitch M, Grad YH. Social distancing strategies for curbing the
432 COVID-19 epidemic. *MedRxiv*. 2020 Jan 1.
- 433 36. Moosa IA. The effectiveness of social distancing in containing Covid-19. *Applied*
434 *Economics*. 2020 Dec 13;52(58):6292-305.

- 435 37. Hsieh CC, Lin CH, Wang WY, Pauleen DJ, Chen JV. The outcome and implications of
436 public precautionary measures in Taiwan–Declining respiratory disease cases in the
437 COVID-19 pandemic. *International journal of environmental research and public health*.
438 2020 Jul;17(13):4877.
- 439 38. Ayouni I, Maatoug J, Dhouib W, Zammit N, Fredj SB, Ghammam R, Ghannem H.
440 Effective public health measures to mitigate the spread of COVID-19: a systematic
441 review. *BMC public health*. 2021 Dec;21(1):1-4.

442 **Tables:**

443 **Table 2-show demographic data frequencies of the participants. (n = 839).**

No.	Demographic variables	Number (n)	Percentage (%)
1	Age (years)		
	18-30	479	57.1
	31-40	164	19.5
	41-55	151	18.0
	56->65	45	5.4
2	Gender		
	Male	536	63.9
	Female	303	36.1
3	Qualification		
	Nil	79	9.4
	Primary	50	6.0
	Secondary	49	5.8
	Intermediate	86	10.3
	Graduate	329	39.2
	Post-graduate	246	29.3
4	Employment status		
	Unemployed or Housewives	211	25.1
	Students	83	9.9
	Paid-employed	289	34.4
	Self-employed	256	30.5
5	Monthly Income (PKR)		
	< 30,000	513	61.1
	> 30,000	326	38.9
6	Ethnicity		
	Pathan	405	48.3
	Kashmiri	353	42.1
	Punjabi	64	7.6
	others	17	2.0
7	Location		
	Peshawar KPK	432	51.5
	Muzaffarabad AJK	407	48.5

8	Hepatitis B positive
----------	-----------------------------

a. Question Statements

	No	436	52.0
	Yes	403	48.0
9	Hepatitis C positive		
	No	403	48.0
	Yes	436	52.0
10	Covid-19 vaccination		
	No	298	35.5
	Yes	541	64.5

444

445 **Table 2- Commercially available Vaccines approved by the Government of Pakistan.**

Approved Vaccines	Type of vaccine
Moderna mRNA 1273	RNA
Pfizer/BioNTech BNT 162b2	RNA
Consino Ad5-NCov	Non-Replicating viral Vector
Gamaleya Spuntik V	Non-Replicating viral Vector
Oxford /Astrazeneca AZD1222	Non-Replicating viral Vector

446

447

Table 3a. Assessment of patients choosing COVID-19 vaccine for protection. Table 2B. Question statements to assess Hepatitis patient for refusing COVID-19 vaccine.

Part A: Why should a hepatitis B or C positive should take Covid-19 Vaccine?	Responses (n=839)	
	No. of participants responded "Yes"	Percentage
I think there is no harm in taking Covid-19 vaccine.	477	72.4%
I believe Covid-19 vaccination will be useful in protecting the Covid-19 infection	507	76.9%
Covid-19 vaccine is available free of cost.	524	79.5%
My healthcare professionals and doctors has recommended me	469	71.2%
I believe that the benefits of COVID-19 vaccine are more than the risk involved	415	63.0%
I believe that taking Covid-19 vaccine is social responsibility	435	66.0%
There is sufficient data regarding the vaccine safety and efficacy released by the government.	374	56.8%
Many other hepatitis B and C are taking COVID-19 Vaccine	504	76.5%

b. Question Statements

Part B: Reason to refuse COVID-19 vaccine	Responses (n=294)	
	No. of patients responded "Yes"	Percentage
I think that it will damage my liver more.	161	54.7 %
I think that COVID-19 vaccine will affect my hepatitis therapy	181	61.5 %
I think that strict SOPs can make me prevent from infection.	218	74.1 %
I do not have enough information about the vaccine.	186	63.2 %
I am against vaccine in general.	158	53.7 %
Due to previous infection with COVID-19, I don't need vaccine	172	58.5 %
People still got covid infection after getting vaccine.	169	57.5 %
After getting first dose I developed some allergic reactions	36	12.2%

448

449 **Table 4a. Correlation between different variables of Hepatitis B and C patients with the Covid-19**
 450 **vaccine approval or rejection. b. Spearman correlation between different variables and COVID-19**
 451 **vaccine.**

452


a.

Variables	Gender	education	location	income	Occupation	Ethnicity	Hepatitis B	Hepatitis C	Covid vaccine	COV 2nd dose	COV booster
Age	↑ 0.124	↔ -0.126	↔ 0.03	↔ 0.016	↔ -0.03	↔ -0.004	↔ -0.126	↑ 0.126	↔ 0.033	↔ -0.015	↑ 0.07
Gender		↑ 0.064	↔ -0.055	↔ -0.095	↑ 0.057	↔ 0.025	↔ -0.08	↑ 0.087	↔ -0.018	↑ 0.093	↔ -0.046
education			↔ -0.137	↔ -0.041	↔ 0.023	↑ 0.05	↑ 0.081	↔ -0.081	↑ 0.09	↑ 0.182	↔ -0.005
location				↑ 0.058	↔ 0.009	↔ -0.034	↔ -0.06	↑ 0.06	↔ -0.022	↑ 0.048	↑ 0.094
income					↔ 0.044	↑ 0.095	↑ 0.075	↔ -0.075	↔ -0.119	↔ -0.106	↑ 0.083
Occupation						↑ 0.082	↔ 0.007	↔ -0.007	↑ 0.104	↑ 0.07	↑ 0.103
Ethnicity							↔ 0.03	↔ -0.03	↔ -0.064	↑ 0.083	↔ 0.044
Hepatitis B								↓ -1	↔ 0.041	↑ 0.096	↔ 0.006
Hepatitis C									↔ -0.041	↔ -0.096	↔ -0.006
Covid vaccine										↑ 0.394	↔ 0.028
COV 2nd dose											↑ 0.209

b.

Variables	Spearman Correlation r	P Value (0.05)
Age	0.033	0.340
Gender	-0.018	0.612
Education	0.064	0.064
Location	-0.022	0.522
Income	-.119	0.001**
Occupation	.107	0.002**
Ethnicity	-0.035	0.309
Hepatitis B	0.041	0.240
Hepatitis C	-0.041	0.240

454 **Figures:**



455

456 **Figure 2a. No. of patients receiving Covid vaccines from approved pharmaceuticals. b. No. of**
 457 **Patients refused to get immunized.**

458